title: Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine.
authors.affiliation: 1The Cerebrovascular Center, Neurological Institute, Cleveland Clinic and Case Western Reserve University, Cleveland, OH.2The Departments of Pharmacy and Anesthesiology & Critical Care Medicine, The Johns Hopkins Hospital and Johns Hopkins University School of Medicine, Baltimore, MD.3The Department of Neurology, Mayo Clinic, Rochester, MN.4Department of Emergency Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA.5The University of Tennessee Health Science Center, Memphis, TN.6Australian Catholic University, Sydney, NSW, Australia.7The Department of Pharmacy, University of Kentucky, Lexington, KY.8The Departments of Medicine (Hematology) and Neurology, University of Washington School of Medicine, Seattle, WA.9The Departments of Neurology, Neurosurgery, Anesthesiology & Critical Care, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.10The Department of Laboratory Medicine and Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, NY.11The Department of Neurosurgery, Westchester Medical Center, New York Medical College, Valhalla, NY.12Hôpital du Sacré-Coeur, Montreal, QC, Canada.13University of Montreal and Montreal Neurological Institute and McGill University, Montreal, QC, Canada.14Department of Neurology, Klinik für Neurologie, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany.15The Neuroscience and Neurosurgery Departments, Centra Lynchburg General Hospital, Lynchburg, VA.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Frontera
authors.forename: John J
authors.initials: JJ
authors.lastname: Lewin
authors.forename: Alejandro A
authors.initials: AA
authors.lastname: Rabinstein
authors.forename: Imo P
authors.initials: IP
authors.lastname: Aisiku
authors.forename: Anne W
authors.initials: AW
authors.lastname: Alexandrov
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Cook
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Del Zoppo
authors.forename: Monisha
authors.initials: M
authors.lastname: Kumar
authors.forename: Ellinor I B
authors.initials: EI
authors.lastname: Peerschke
authors.forename: Michael F
authors.initials: MF
authors.lastname: Stiefel
authors.forename: Jeanne S
authors.initials: JS
authors.lastname: Teitelbaum
authors.forename: Katja E
authors.initials: KE
authors.lastname: Wartenberg
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Zerfoss
mesh_terms: D003422:Critical Care / Q000592:standards*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000517:prevention & control*; D009462:Neurology / Q000592:standards*; D055502:Secondary Prevention / Q000379:methods; D012955:Societies, Medical / Q000592:standards; D013923:Thromboembolism / Q000188:drug therapy; D014481:United States
chemical_list: D005343:Fibrinolytic Agents